$404.00
3.24[0.81%]
At close: Apr 24
$404.00
0[0.00%]
After Hours: 6:26PM EDT
Vertex Pharmaceuticals
(NASDAQ:VRTX)Vertex Pharmaceuticals Stock (NASDAQ:VRTX), Analyst Ratings, Price Targets, Predictions
Vertex Pharmaceuticals Inc has a consensus price target of $361.69, established from looking at the 100 latest analyst ratings. The last 3 analyst ratings were released from Guggenheim, UBS, and Oppenheimer on April 18, 2024, April 17, 2024, and April 15, 2024. With an average price target of $472 between Guggenheim, UBS, and Oppenheimer, there's an implied 16.83% upside for Vertex Pharmaceuticals Inc from these 3 analyst ratings.
Analyst Firms Making Recommendations1
Guggenheim
UBS
Oppenheimer
Canaccord Genuity
HC Wainwright & Co.
1calculated from analyst ratings published within the last 3 years
Analyst Ratings for Vertex Pharmaceuticals
date | ticker | Buy Now | Company | Current price | Upside/Downside | Analyst Firm | Analyst & % Accurate | Price Target Change | Rating Change | Previous / Current Rating | Get Alert |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 04/18/2024 | VRTX | Buy Now | Vertex Pharmaceuticals | $404.00 | 11.39% | Guggenheim | Debjit Chattopadhyay | $445 → $450 | Maintains | Buy | Get Alert |
| 04/17/2024 | VRTX | Buy Now | Vertex Pharmaceuticals | $404.00 | 15.35% | UBS | Colin Bristow | $498 → $466 | Maintains | Buy | Get Alert |
| 04/15/2024 | VRTX | Buy Now | Vertex Pharmaceuticals | $404.00 | 23.76% | Oppenheimer | Hartaj Singh | → $500 | Maintains | Outperform | Get Alert |
| 04/12/2024 | VRTX | Buy Now | Vertex Pharmaceuticals | $404.00 | -8.17% | Canaccord Genuity | Whitney Ijem | $371 → $371 | Maintains | Sell | Get Alert |
| 04/11/2024 | VRTX | Buy Now | Vertex Pharmaceuticals | $404.00 | 14.36% | HC Wainwright & Co. | Andrew Fein | $457 → $462 | Maintains | Buy | Get Alert |
| 04/11/2024 | VRTX | Buy Now | Vertex Pharmaceuticals | $404.00 | 8.42% | Evercore ISI Group | Liisa Bayko | → $438 | Upgrade | In-Line → Outperform | Get Alert |
| 02/20/2024 | VRTX | Buy Now | Vertex Pharmaceuticals | $404.00 | 8.91% | Cantor Fitzgerald | Olivia Brayer | → $440 | Reiterates | Overweight → Overweight | Get Alert |
| 02/15/2024 | VRTX | Buy Now | Vertex Pharmaceuticals | $404.00 | — | Wolfe Research | Andy Chen | — | Initiates | → Outperform | Get Alert |
| 02/06/2024 | VRTX | Buy Now | Vertex Pharmaceuticals | $404.00 | 8.91% | Cantor Fitzgerald | Olivia Brayer | → $440 | Reiterates | Overweight → Overweight | Get Alert |
| 02/06/2024 | VRTX | Buy Now | Vertex Pharmaceuticals | $404.00 | 11.39% | JP Morgan | Jessica Fye | $438 → $450 | Maintains | Overweight | Get Alert |
| 02/06/2024 | VRTX | Buy Now | Vertex Pharmaceuticals | $404.00 | 33.66% | Wells Fargo | Mohit Bansal | $500 → $540 | Maintains | Overweight | Get Alert |
| 02/06/2024 | VRTX | Buy Now | Vertex Pharmaceuticals | $404.00 | 3.96% | RBC Capital | Brian Abrahams | $397 → $420 | Maintains | Sector Perform | Get Alert |
| 02/06/2024 | VRTX | Buy Now | Vertex Pharmaceuticals | $404.00 | 16.83% | Barclays | Gena Wang | $446 → $472 | Maintains | Overweight | Get Alert |
| 02/06/2024 | VRTX | Buy Now | Vertex Pharmaceuticals | $404.00 | 8.42% | Evercore ISI Group | Liisa Bayko | $436 → $438 | Downgrade | Outperform → In-Line | Get Alert |
| 02/06/2024 | VRTX | Buy Now | Vertex Pharmaceuticals | $404.00 | 13.12% | HC Wainwright & Co. | Andrew Fein | $397 → $457 | Maintains | Buy | Get Alert |
| 02/02/2024 | VRTX | Buy Now | Vertex Pharmaceuticals | $404.00 | — | Bernstein | William Pickering | — | Downgrade | Outperform → Market Perform | Get Alert |
| 02/01/2024 | VRTX | Buy Now | Vertex Pharmaceuticals | $404.00 | 8.42% | JP Morgan | Jessica Fye | $390 → $438 | Maintains | Overweight | Get Alert |
| 01/31/2024 | VRTX | Buy Now | Vertex Pharmaceuticals | $404.00 | 25.74% | Truist Securities | Robyn Karnauskas | $456 → $508 | Maintains | Buy | Get Alert |
| 01/31/2024 | VRTX | Buy Now | Vertex Pharmaceuticals | $404.00 | 38.37% | Goldman Sachs | Salveen Richter | $442 → $559 | Maintains | Buy | Get Alert |
FAQ
What is the target price for Vertex Pharmaceuticals (VRTX)?
The latest price target for Vertex Pharmaceuticals (NASDAQ: VRTX) was reported by Guggenheim on April 18, 2024. The analyst firm set a price target for $450.00 expecting VRTX to rise to within 12 months (a possible 11.39% upside). 84 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Vertex Pharmaceuticals (VRTX)?
The latest analyst rating for Vertex Pharmaceuticals (NASDAQ: VRTX) was provided by Guggenheim, and Vertex Pharmaceuticals maintained their buy rating.
When was the last upgrade for Vertex Pharmaceuticals (VRTX)?
The last upgrade for Vertex Pharmaceuticals Inc happened on April 11, 2024 when Evercore ISI Group raised their price target to $438. Evercore ISI Group previously had an in-line for Vertex Pharmaceuticals Inc.
When was the last downgrade for Vertex Pharmaceuticals (VRTX)?
The last downgrade for Vertex Pharmaceuticals Inc happened on February 6, 2024 when Evercore ISI Group changed their price target from $436 to $438 for Vertex Pharmaceuticals Inc.
When is the next analyst rating going to be posted or updated for Vertex Pharmaceuticals (VRTX)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Vertex Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Vertex Pharmaceuticals was filed on April 18, 2024 so you should expect the next rating to be made available sometime around April 18, 2025.
Is the Analyst Rating Vertex Pharmaceuticals (VRTX) correct?
While ratings are subjective and will change, the latest Vertex Pharmaceuticals (VRTX) rating was a maintained with a price target of $445.00 to $450.00. The current price Vertex Pharmaceuticals (VRTX) is trading at is $404.00, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.